ENYO Pharma announces positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks
- NEWS RELEASE
ENYO Pharma (France) announced on 28 July, 2021, positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks.
For detailed information, see the URL below.
Vonafexor is a synthetic non-steroidal, non-Bile Acid, highly selective FXR agonist. This is used the STAM™ mouse model for non-clinical studies, and data showing the improvement of NASH and fibrosis in the STAM™ mouse model was presented at AASLD 2019.
In the future, we believe that further clinical trial results for Vonafexor will provide evidence for the STAM™ mouse model as a clinically predictive NASH model.